BioMarin Pharmaceutical Inc. : BioMarin to Present at the Baird Growth Stock Conference
05/08/2012| 10:43am US/Eastern
Recommend:
NOVATO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- BioMarin
Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Hank
Fuchs, M.D., Chief Medical Officer at BioMarin, will present
a company update at the Baird Growth Stock Conference in
Chicago on Thursday, May 10, 2012 at 12:40 p.m. CT.
Interested parties may access a live audio webcast of the
conference call via the investor section of the BioMarin
website, www.BMRN.com. A
replay of the call will be archived on the site for one week
following the call.
About BioMarin
BioMarin develops and commercializes innovative
biopharmaceuticals for serious diseases and medical
conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical
product candidates. Approved products include Naglazyme®
(galsulfase) for mucopolysaccharidosis VI (MPS VI), a product
wholly developed and commercialized by BioMarin; Aldurazyme®
(laronidase) for mucopolysaccharidosis I (MPS I), a product
which BioMarin developed through a 50/50 joint venture with
Genzyme Corporation; Kuvan® (sapropterin dihydrochloride)
Tablets, for phenylketonuria (PKU), developed in partnership
with Merck Serono, a division of Merck KGaA of Darmstadt,
Germany; and Firdapse™ (amifampridine), which has been
approved by the European Commission for the treatment of
Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates
include GALNS (N-acetylgalactosamine 6-sulfatase), which is
currently in Phase III clinical development for the treatment
of MPS IVA, amifampridine phosphate (3,4-diaminopyridine
phosphate), which is currently in Phase III clinical
development for the treatment of LEMS in the U.S., PEG-PAL
(PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase II clinical development for the treatment
of PKU, BMN-701, a novel fusion protein of insulin-like
growth factor 2 and acid alpha glucosidase (IGF2-GAA), which
is currently in Phase I/II clinical development for the
treatment of Pompe disease, BMN-673, a poly ADP-ribose
polymerase (PARP) inhibitor, which is currently in Phase I/II
clinical development for the treatment of genetically-defined
cancers, and BMN-111, a modified C-nutriuretic peptide, which
is currently in Phase I clinical development for the
treatment of achondroplasia. For additional information,
please visit www.BMRN.com.
Information on BioMarin's website is not incorporated by
reference into this press release.
BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered
trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme
LLC.
CONTACT: Investors
Eugenia Shen
BioMarin Pharmaceutical Inc.
(415) 506-6570
Media
Bob Purcell
BioMarin Pharmaceutical Inc.
(415) 506-3267
Image: BioMarin Pharmaceutical Inc. Logo
BioMarin Pharmaceutical Inc.
distributed by
|
|
Recommend :
